ClinicalTrials.gg
TerminatedNCT00479765Updated Jun 22, 2022Results posted

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

A Phase 1/2 interventional study of OncoGel (ReGel/Paclitaxel) in Glioblastoma Multiforme and Brain Neoplasms, sponsored by Boston Scientific Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-22.

Sponsored by Boston Scientific Corporation · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor business decision, not based on safety or efficacy data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
1,061st of 1,155
4 · median 33
Started
2007
with 45 others
Phase 1/2
190 of 1,302
32 open now
Registered
254th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 1,061st largest by enrollment of the 1,155 interventional ones that give a count, is one of 46 that started in 2007, is one of 190 in phase 1/2, and was the 254th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

OncoGel™ is a new, experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel™) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel.

The purpose of this study is to evaluate the safety and tolerability of OncoGel when placed into the tumor resection cavity in the brain following surgical removal of the tumor. Dose escalation is conducted by gradually increasing the amount of OncoGel placed in the resection cavity in small groups of patients, and watching the patients closely for side effects before moving to the next dose level. The study will also test whether OncoGel helps to prevent or delay the tumor from regrowing.

Read the detailed description

This study is for patients with recurrent glioblastoma multiforme. Because most recurrences are in the area of the original resection, local delivery of a chemotherapeutic agent may prevent or delay additional recurrences. Paclitaxel has demonstrated activity against 9L glioma tumor lines, but has poor central nervous system penetration after intravenous administration. OncoGel is a new formulation of paclitaxel in a bioerodible gel that can be administered directly to the brain, thereby bypassing the blood-brain barrier.

03

Conditions studied

  • Glioblastoma Multiforme
  • Brain Neoplasms

Keywords

  • glioblastoma multiforme
  • recurrent
  • Phase 1
  • Phase 2
  • Phase I
  • Phase II
  • brain
  • cancer
  • paclitaxel
  • intracranial
  • tumor
  • local
  • chemotherapy
  • brain tumor
  • brain cancer
  • glioma
  • OncoGel
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 to less than 70 years of age
  • Radiological evidence on MRI of progressive recurrent malignant glioma that is unilateral, unifocal, supratentorial and of the minimum tumor volume as required per dose level assignment
  • Tumor must have a solid contrast enhancing component
  • Gross total resection >95% of the recurrence must be planned
  • Must have received prior conventional radiation therapy completed >4 weeks before Study Day 1 (ie, day of craniotomy and OncoGel administration)
  • Previous cytoreductive surgery or with pathologic diagnosis of glioblastoma multiforme
  • Diagnosis of glioma at the time of debulking surgery for recurrence (by frozen section or squash preparation)
  • > 2 months
  • greater than or equal to 70
  • Using appropriate , if female of ;
  • Able and willing to participate in the study by signing the document

Exclusion criteria

Exclusion Criteria:

  • Contrast-enhancing tumor crossing the midline
  • Multifocal or non-contiguous tumor resulting in multiple resection cavities
  • Evidence of tumor dissemination (ependymal, )
  • Tumors that result in a lobectomy or after resection leave an insufficient residual cavity to receive the expected OncoGel volume
  • Expected communication between the ventricle and resection cavity that cannot be repaired
  • Involvement of primary sensorimotor cortex in the dominant hemisphere or within 1.5 cm of the optic chiasm, either optic nerve or any other cranial nerve
  • Significantly increased intracranial pressure
  • Received any type of stereotactic radiosurgery or brachytherapy with the exception of a stereotactic radiosurgery boost as part of the initial radiation therapy
  • History of seizures to two or more anticonvulsant medications co-administered at therapeutic levels
  • Impaired organ function as evidenced by laboratory parameters including but not limited to the following: Hepatic Status: >2.0 mg/dL; (AST) >2.5 times the normal limit; Alanine aminotransferase (ALT) >2.5 times the normal limit. Hematopoietic Status: (ANC) \<1500mm3; count \<100,000/mm3; \< 10 g/dL. Hemostatic: (PT) or INR above normal range; Partial Thromboplastin Time (PTT) above normal range; Bleeding Time outside normal range (if performed by hospital). Renal Status: Serum creatinine >2 mg/dL.
  • to MRI
  • Receipt any chemotherapeutic agent within 28 days of Study Day 1 or nitrosourea within 6 weeks of Study Day 1
  • Received any intracerebral agent
  • Receipt of another investigational drug or device within 28 days of the planned surgery
  • Known history of allergy to paclitaxel or any other component of OncoGel
  • Pregnant or lactating
  • Concurrent life-threatening disease
  • Any medical condition or other circumstance that, in the opinion of the Investigator, would make the subject unlikely or unable to successfully complete the study, or would interfere with analysis of study results
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    1

    OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel

    Drug: OncoGel (ReGel/Paclitaxel)

Interventions

  • DrugOncoGel (ReGel/Paclitaxel)

    Drug page: Paclitaxel

    OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.

06

What researchers measure

Primary outcomes

  1. Occurence of Dose-limiting Toxicities (DLTs)

    any evidence or sign of a dose-limiting toxicity after administration to determine the maximum tolerated dose (MTD)

    Time frame: 8 weeks

07

Results

Posted May 15, 2014

Participant flow

Participant flow — Overall Study
MilestoneOncoGel
Started4
Completed0
Not completed4
Withdrew: Study terminated4

Outcome measures

PrimaryOccurence of Dose-limiting Toxicities (DLTs)

any evidence or sign of a dose-limiting toxicity after administration to determine the maximum tolerated dose (MTD)

Time frame:
8 weeks
Reported as:
Number · dose limiting toxicities
Occurence of Dose-limiting Toxicities (DLTs)
dose limiting toxicitiesOncoGel 5mL
Occurence of Dose-limiting Toxicities (DLTs)0

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OncoGel 5mL—2/4 (50%)0/4 (0%)
Most frequent serious events
Most frequent serious events
EventOncoGel 5mL
subdural hematomaVascular disorders2/4

Baseline characteristics

Four subjects were dosed with 5% Oncogel prior to study termination.

Age, Continuous
Age, Continuous(years)OncoGel 5mL
Mean60 (46 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)OncoGel 5mL
Female0
Male4
08

Study locations

5 sites
  • The University of Chicago Brain Tumor Center
    Chicago, Illinois 60637, United States
  • The Johns Hopkins University
    Baltimore, Maryland 21231, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 4 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 28, 2007
Start
Mar 2007
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
May 15, 2014
Last update
Jun 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00479765
Responsible party
Sponsor
First posted
May 28, 2007
Start date
Mar 2007
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
May 15, 2014
Last update
Jun 22, 2022

Study contacts

Maciej S Lesniak, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion